Category: Press Releases

Takeda and PvP Biologics Announce Development Agreement around Novel Therapeutic for Celiac Disease

January 5, 2017

Osaka, Japan, January 6, 2017, San Diego, Calif., USA, and Seattle, Wash., USA, January 5, 2017 – Takeda Pharmaceutical Company Limited (“Takeda”) (TSE: 4502) and PvP Biologics, Inc. (“PvP”) today announced a global agreement for the development of KumaMax, a novel enzyme designed to break down the immune-reactive parts of gluten in the stomach, thereby…

Read More

PvP Biologics Announces Leadership Team

January 5, 2017

SAN DIEGO and SEATTLE, January 5 – PvP Biologics today announced the company’s leadership team. The company was formed to advance an oral enzyme therapy, called KumaMax, for the treatment of celiac disease. Currently in pre-clinical development, KumaMax is a uniquely engineered, recombinant enzyme that is active under acidic stomach conditions and has high specificity…

Read More

UW Spin-Out Seeks to Develop Celiac Disease Therapy

December 20, 2016

SEATTLE and SAN DIEGO, Dec. 20, 2016 – PvP Biologics, a University of Washington spin-out, is advancing a scientifically designed enzyme that could help people with celiac disease. The UW Institute for Protein Design created the enzyme, called KumaMax. It targets parts of gluten that cause the autoimmune reaction leading to celiac disease. The disease…

Read More